Novartis Raises Guidance as Key Drugs Boost Sales




Novartis now expects its core operating profit to grow in the mid to high teens, after second-quarter results outpaced analysts’ expectations, boosted by revenue from its blockbuster treatments.

Leave a Reply

Your email address will not be published. Required fields are marked *